Purpose of Review We synthesised the literature on productivity losses and costs in the less-common systemic autoimmune rheumatic diseases: Sjogren's syndrome (SjS), systemic sclerosis (SSc), poly/dermatomyositis (PM/DM), and systemic vasculitides (SV). Recent Findings Of 29 studies located, 12 were published 2012 onwards (SSc = 6, SjS = 2, PM/DM = 2, SV = 2). In these, 25% of PM/DM, and 21-26% of SV, were work disabled, 22% of SSc stopped work within 3 years of diagnosis, and annual costs of absenteeism in SSc averaged $12,024 2017 USD. Very few studies reported on costs, presenteeism (working at reduced levels), or unpaid productivity loss. Across multiple systemic autoimmune rheumatic diseases (SARDs), major drivers of lost productivity were generalised items like pain, depression, and fatigue, rather than diseasespecific factors. Summary Evidence suggests that work disability is common in SSc and strikes quickly. However, in SSc and other SARDs, more comprehensive estimates are needed, which include absenteeism and presenteeism from paid and unpaid work, costs, and drivers of productivity loss.
Introduction
Systemic autoimmune rheumatic diseases (SARDs) are a group of chronic arthritides including systemic lupus erythematosus (SLE), Sjogren's syndrome (SjS), systemic sclerosis/ scleroderma (SSc), polymyositis and dermatomyositis (PM/ DM), and forms of adult systemic vasculitides. Though distinct disorders, SARDs are often studied together due to shared pathogenesis, manifestations, and treatments.
Immune dysregulation in SARDs results in systemic inflammation, organ damage, and a high morbidity burden that is compounded by the adverse effects of immune-modulating and immunosuppressive therapies. Altogether the physical, psychological, and neurocognitive manifestations of SARDs can lead to high levels of health care resource use and costs [1] [2] [3] [4] [5] [6] and reduced health-related quality of life [7] [8] [9] [10] [11] [12] , and limit participation in paid employment [13, 14] , and family [15] [16] [17] and other meaningful activities [18, 19] . These effects can strike early, with 26% of working-age SjS [20••] , and 28% of SSc [21] , unable to work for pay within 2 years of diagnosis. In earlier reports from Canada, the lost productivity costs of SLE and SSc exceeded the direct medical costs (i.e. costs for hospitalisations, physician visits, and medications) by twofold to threefold [22] [23] [24] .
Productivity losses, which encompass time lost from paid and unpaid work activities, take many forms including work disability (leaving the paid workforce work due to health), absenteeism (work time missed due to health), and 'presenteeism' (working, but at a reduced level/efficiency). Estimates of lost productivity are useful in informing health policy, allocating scarce resources, and setting research and This article is part of the Topical Collection on Health Economics and Quality of Life treatment priorities. Moreover, knowledge of the drivers and predictors of productivity loss can inform efforts to help reduce (or even prevent) these losses.
SLE is the most common SARD and several reviews [13, [25] [26] [27] [28] [29] are available on the productivity burden of this disease. But whilst recent reports show other SARDs, such as SSc, PM/DM, and systemic vasculitides (SV), being associated with high health care costs [2, 3, 5, 6] , their productivity burden remains largely unknown. A 2012 review on the economic burden of SV [30] profiled just two productivity studies, and whilst two systematic reviews are available on employment in SSc [14, 31] , they do not include studies published after 2012. Here, we review the existing literature on productivity losses in these 'lesser-known' SARDs (SSc, Sjogren's, poly/dermatomyositis, and systemic vasculitides) to summarise what is known about the extent and drivers of their productivity burden, and identify gaps and directions for future research.
How Are Productivity Losses Assessed?
Whilst an extensive discussion of productivity and health is beyond the scope of this review, we begin with a brief overview of the components of productivity loss and how they are measured and valued. Readers wishing more information are encouraged to consult the following resources [32] [33] [34] [35] .
A compromised health state can affect one's performance of both paid and unpaid work, with the specific types of unpaid work (i.e. housework, yard work, childrearing, studying, volunteering) varying across studies. Lost productivity can be measured as a categorical outcome (employed: yes/no) or continuously (absenteeism and presenteeism), in units of time (i.e. hours or days of presenteeism, absenteeism, or long-term disability), money, or both. Estimates of productivity costs (sometimes called indirect costs) are produced by assigning a monetary value to the time estimates (i.e. multiplying hours/ days by an hourly/daily wage). Although there is now a movement away from using the terms direct and indirect [33] , direct costs refer to costs for the provision of goods or services, such as laboratory tests or medications. Productivity costs are considered indirect since costs are incurred (i.e. a business's production decreases when an employee is not working at full capacity) but not paid out to any party. Whilst productivity costs are not always considered by health care payers in decision-making, they are relevant from a societal perspective, and should be assessed and reported when possible [35] .
Estimates of lost productivity costs will vary depending upon the methods used to value work. If time losses from unpaid work are valued using the average wages of individuals hired to do the same work, such as housecleaners or childcare workers (the replacement cost method [33] ), costs will usually be lower than when using the same wages one would receive in their paid job (the opportunity cost method [33] ). Bowman et al.'s [36] 2010 estimates of the lost productivity costs of Sjogren's in the United Kingdom (UK) illustrate how cost estimates are influenced by the components included, and how they are valued. They considered time patients missed from paid and unpaid work, and time helpers missed from paid work when accompanying the patient to medical appointments. Employed patients were asked about the actual number of sick days taken, additional hours they would regularly work in the absence of health problems, and additional weeks of work missed per year due to illness. Time losses from unpaid work were valued using both replacement and opportunity costs. With these different measures of patients' and carers' paid work loss, and patients' unpaid work loss, they produced six estimates ranging from $12,730 (converted to 2017 USD), which included sick days from paid work, and valued unpaid work losses with the replacement wage, to $22,390, which included all three aspects of paid work loss, and used sex-and age-matched average wages to value unpaid work losses.
The measurement and valuation of productivity losses is subject to equity concerns that are especially relevant in SARDs, as they predominantly affect females. Some SARDs, like SLE, strike mainly between the ages of 20 and 50, patients' peak career and childrearing years. Others, like Sjogren's and giant cell arteritis, affect mainly those over 50, some of whom may already have retired. Estimates of paid work losses alone will exclude the time contributions of homemakers, students, and those retired for health or other reasons. Valuing productivity losses with age-and sexspecific wages can also undervalue the time of females (whose wages are typically lower), and those in lower-paying occupations. The implications of these choices are illustrated in a well-cited paper by Clarke et al. [37] , who assessed the annual productivity costs of females with SLE under five scenarios that varied the type of work considered (paid only, or paid and unpaid), wages (overall or sex-specific), and valuation of unpaid time (replacement or opportunity costs). Estimates ranged from $9776 (2017 USD), for 12-month losses from paid work, to $21,120, when including time lost from paid and unpaid work, and using males' average wages to value unpaid productivity loss.
Prior Work
Numerous studies have been conducted on work disability (WD) and productivity losses and costs in SLE, and these have been summarised and critiqued in several reviews [13, [25] [26] [27] [28] [29] . In a systematic review and meta-analysis of 26 studies [13] , 46% (95% CI 40-52%) of SLE were employed whilst 34% (24-44%) were work disabled (WD). Patient factors associated with WD included lower education and socioeconomic status, decreased physical functioning, higher disease activity, and higher levels of pain, fatigue, and anxiety, whilst job/workplace factors included greater physical demands and less control. A systematic review on costs of SLE [25] found that poor physical or mental health, less social support, higher educational attainment, and high disease activity were associated with higher lost productivity costs.
Therefore, whilst gaps remain in our understanding of lost productivity in SLE, we decided to focus this review on the other SARDs (SSc, Sjogren's, poly/dermatomyositis, and SV), where far less is known about their productivity burden. We will briefly review the earlier literature (published before 2012), before detailing and critiquing the most recent reports. Our review is restricted to studies published in English (thus excluding at least two articles [38, 39] ), and reporting quantitative data on employment/work disability rates, absenteeism, presenteeism, or costs. All reported costs were converted to 2017 USD.
SSc
SSc was discussed in the majority (11/17) of studies (Table 1) . Lost productivity costs, reported in three [22, 44, 50] , ranged from $8592 in Hungary to $13,796 in the USA, and $14,584 in Canada. Forty percent of costs in the Canadian cohort were for time lost from paid work (43% of costs for the diffuse subset (dcSSc) and 36% for the limited (lcSSc)). Nine studies assessed WD, with prevalence ranging from 19% [50] to 61% [45] (Table 1 ). In one [46] , WD was significantly more frequent in SSc than RA (56 vs. 35%, p = 0.01), whilst in a tenth study [43] , employment rates were significantly lower in SSc than the general population (standardised employment ratio = 0.77). Determinants of WD and productivity varied, but included disease duration [21, 42, 46] , subtype [21, 46] , hand function [42, 47, 48] , fatigue [21, [47] [48] [49] , pain [21, 48] , education [49] , social support [49] , and self-rated health [45, 47] . Nearly all were cross-sectional studies, but in the one longitudinal investigation [49] , lung involvement and fatigue at enrolment, and non-Caucasian ethnicity, were significant predictors for becoming WD.
SjS
The lost productivity costs of SjS were reported in the Bowman et al. [36] paper described previously, whilst WD was reported in two others. In a US study [40] , 12% were WD (vs. none in the sex and age-matched comparison group), and WD individuals had higher levels of pain, depression, and cognitive dysfunction than non-WD. A Dutch report [41] found that SjS were less likely to be employed full-time (10 vs. 24%) or at all (51 vs. 83%), compared to the general population, and employed SjS worked fewer hours per week than non-SjS (22 vs. 27 ). Higher education was associated with being employed.
Systemic Vasculitides
The earlier studies reported on just one condition, granulomatosus with polyangiitis (GPA), formerly known as Wegener's disease. In related studies of GPA patients in the USA and Netherlands, 77% of employed GPA in the US cohort (80% in the Netherlands [51] ) reported taking more than six consecutive weeks of sick leave, with 57% [53] /53% [51] US/Dutch taking more than six consecutive months of leave. More than half had to modify their jobs or take total disability, with 51% [53] /41% [51] reducing work hours, 37% changing duties [53] , 17% [53] /5% [51] resigning, and 31% of the US cohort (27% of the Dutch [52] ) receiving disability benefits. Reinhold-Keller et al. [54] studied a German cohort of prevalent GPA who were aged ≤40 years at diagnosis. Sixteen of 60 individuals were WD, and far more females than males (78 vs. 29%) had become unemployed since GPA diagnosis, though not all work loss was due to GPA. Finally, in another German analysis [43] , the standardised employment ratio for GPA (0.76) was the lowest amongst all six rheumatic diseases studied.
Recent Research (2012-Present)
Turning our attention to the most recent work in the field, we located 12 studies published in the past 5 years (2012 onwards), whose characteristics are in Table 2 . Eight were from Europe [20, 55•, 56-58, 59 •, 61••, 63], one Australia [60] , two the USA [1, 62] , and one was from Canada [64] . Six reported on SSc [57] [58] [59] [60] [61] [62] , two on SV [63, 64] , two on PM/DM [1, 55] , and two on SjS [20••, 56] . As the earlier estimates focussed mainly on SSc, it was encouraging to see more studies emerge on other SARDs. However, some gaps remain, with few studies reporting on presenteeism [62, 64] , patients' unpaid work loss [62] , or costs [58, 59•, 62] . Moreover, heterogeneity in the definitions and measures of productivity loss (i.e. employment yes/no, work disability for any health reason vs. the SARD specifically, days vs. hours of presenteeism), and methods used to monetise these losses, limits the comparability of estimates across studies.
SSc
Three studies in SSc reported on productivity costs. In the first [59•] , which had estimates from seven European countries, carers' time losses from paid work were valued using country-specific wages for professional caregivers, and absenteeism for patients was valued using country-specific (and, in In the second study [62] , members of the UCLA Scleroderma Quality of Life cohort were asked about days of absenteeism (work days missed) and presenteeism (days where work productivity was reduced by ≥50%) from both paid and unpaid work. Twenty-four percent of the cohort were WD due to SSc; factors significantly associated with WD included higher disability (measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)) and lower education. Amongst those in the paid workforce, those with lcSSc had significantly more days of absenteeism and presenteeism than dcSSc. Lower education and poorer overall health were associated with productivity loss from paid work, whilst having lcSSc or worse HAQ-DI scores were associated with productivity loss from unpaid work. Lost productivity costs (defined as lost earnings, which may not represent the societal costs) for those in paid work were valued using sexand education-specific median weekly earnings, and averaged $1002 per month ($12,024 annually); those for WD individuals averaged $47,952 annually. Despite this being one of few studies reporting on presenteeism and unpaid productivity losses, costs were not computed for these components, perhaps because time loss was measured in days instead of hours. Moreover, as with the aforementioned European estimates, there are equity concerns associated with the use of sexspecific wages to value time loss in a disease that predominantly affects females.
In the third cost study [58] , data from the Social Insurance Institution in Poland were used to assess the costs of sick days, and short-and long-term disability, from paid work. Depending on the method of valuation, mean per-person costs ranged from $3876 to $12,677. Sick days accounted for 19% of costs, short-term disability 5%, and long-term disability 77%. Whilst the national social insurance database made the estimates more generalisable, neither presenteeism nor This article reported on costs from each of the seven European countries that participated in this study. The findings from Spain [73] and France [65] are also reported separately. 95% CI: 95% confidence interval, EGPA= Eosinophilic Granulomatosis with polyangiitis (Churg-Strauss syndrome), GCA=giant cell arteritis, GPA=Granulomatosus with polyangiitis, IQR=interquartile range, MPA=Microscopic polyangiitis, pSjS=primary Sjogren's syndrome, PAN=polyarteritis nodosa, RR=relative risk, WLQ=Work Limitations Questionnaire productivity loss from unpaid work were captured in the database, so were not included in the costs. Three other studies reported on WD in SSc, but not costs, with 40% of a working-age, clinic-based cohort in Belgium being WD [57] and 20% of an Australian clinic-based cohort not employed [60] . Although working-age participants in the former study were asked about several health-related work transitions, the majority had stopped working entirely instead of reducing their hours or changing jobs. In the latter study, having dcSSc, a physical job, pulmonary hypertension, sicca symptoms, or digital amputation were all significantly associated with unemployment.
Finally, in the first of two longitudinal studies from Sweden (one on SSc and one on SjS), routinely collected data were used to assess WD in a working-age cohort of newly diagnosed SSc, and a reference group from the general population [61••] . WD was assessed each month, continuously and categorically (any sick leave or disability days), using data from the Swedish Social Insurance Agency. Of the 25 SSc who had no WD at diagnosis, 25% had more than 90 days of WD during the first 3 years after diagnosis, and 22% were on full-time WD. Those with dcSSc averaged more days of WD, and were more likely to develop full WD. No disease-related factors correlated significantly with WD, but education level, number of years in the workplace, and sickness absence in the month prior to SSc diagnosis were correlated with cumulative WD days over the 3 years following diagnosis.
SjS
The second longitudinal study [20• •] employed a similar design, and sourced the same routinely collected data, to study WD in a cohort of working-age SjS. Twenty-six percent of SjS had any WD at diagnosis, and this number rose to 37% at 12 months, and 41% at 24 months. Older age, being on sick leave or disability at the time of SjS diagnosis, and having fibromyalgia all increased the odds for being WD at 24 months, though disease activity did not. Days of WD averaged 6.2 per month at the time of diagnosis, 9.2 at 12 months, and 10.2 at 24 months. A key feature of these two Swedish studies was the population-based data source, which minimised selection and recall bias, and enabled comparison between SSc/SjS and the general population (four non-SSc/SjD individuals for each SSc/SjD). However, data were not available on presenteeism or time loss from unpaid work, nor absences of less than 14 days, since these losses are not compensated by the Swedish Social Insurance Agency.
German investigators compared the productivity of working-age females with SjS attending one of four tertiary clinics, with a sample of their similarly aged female friends without SjS [56] . Fifty-three percent of SjS were employed, as were 77.1% of non-SjS. Employed SjS reported more days of sick leave over the past 6 months than non-SjS (19.8 vs. 4.5), and 10.4% of SjS (vs. 1.5% of non-SjS) were on currently sick leave. In addition, retired SjS had stopped working earlier than retired non-SjS, at mean age of 47.9 ± 8.5 vs. 57.5 ± 4.5 years. Age, disease duration, functional capacity, and lack of stamina were all predictive of employment status, whilst pain and dryness were not. Though admirable that data were collected for a non-SjS comparison group, one concern is that 'friend controls' (used in an earlier SjS study [40] as well) may not be representative of the broader population.
SV
Two recent studies have extended our knowledge of productivity loss in SV beyond GPA. In one, conducted at a tertiary rheumatology centre in Ontario, Canada [64] , 43% of 51 working-age SV were WD, defined as not working (59%), took early retirement (14%), or working reduced hours (27%). WD participants had greater functional impairment (HAQ scores of 0.86 vs. 0.14), more pain, organ system involvement, and disease activity and damage, and were less educated. Amongst those still employed, productivity loss due to health (measure of presenteeism) averaged 8.2%, and was correlated with HAQ and pain scores, but not age, disease duration, or levels of disease activity or damage.
In the second, Basu et al. [63] assessed factors associated with WD in a hospital-based, UK cohort of working-age individuals with ANCA-associated vasculitis. Twenty-six percent were WD (not working due to health), with fatigue, overweight, depression, and severe disease damage all increasing the odds of WD, whilst no other clinical factors (i.e. disease activity, subtype, therapies, ANCA status) did. Unfortunately, neither of these studies had data for a non-SV comparison group, and whilst the Canadian study only reported on WD that participants considered SV-related, this may be difficult to attribute.
PM/DM
In 2016, the first-known studies of productivity loss in PM/ DM were published. One, reporting on a Swedish myositis registry [55•] , found that 44% of working-age participants were working full-time, and 31% part-time, whilst 25% were on full-time sick leave. The second used a commercial health care claims database to estimate medically related work loss (absenteeism and disability claims) for a cohort of employed PM/DM with disability insurance, and a non-PM/DM matched comparison group [1] . Though disability claims were captured directly from the database, no other productivity data were available, so estimates of medically related absenteeism were determined from health care utilisation claims. An emergency room visit or day in hospital during the workweek counted as one full day of missed work, and outpatient medical visits counted as a half-day. They found that PM/DM averaged 2.0 more days of work loss over a 12-month period than did the non-PM/DM, driven more by medically related absenteeism.
Whilst the administrative claims database allowed for a larger sample size than the registry study (n = 611 vs. 48), and facilitated access to data for a non-PM/DM comparison group, it did not allow for assessment of presenteeism or unpaid work loss. Furthermore, the use of health care encounters as a proxy for medically related absenteeism was problematic, with the authors themselves acknowledging that they did not know whether utilisation actually occurred during individuals' working hours.
Discussion
In summarising the literature on productivity losses and costs i n t h e l e s s e r -k n o w n S A R D s ( S S c , S j o g r e n 's , poly/dermatomyositis, systemic vasculitides), we located 29 studies, with 12 published over the past 5 years. Most focussed on SSc, and in these, SSc was associated with high rates of work disability and substantial productivity costs. However, there remain several gaps in the literature that are limiting our understanding of the incremental productivity losses and costs of SSc and other SARDs. The types of productivity losses that have been assessed, how they were monetised, and the study populations and data sources used, merit further discussion.
Completeness of Estimates
Although presenteeism is recognised as a major driver of productivity loss [32] , accounting for 41% of losses in one study of arthritis [67] , just three of 29 studies reported on presenteeism [42, 62, 64] , and there were little data on productivity losses from unpaid activities [22, 36, 42, 50, 62] . Ideally, productivity studies should collect data on participation in paid work (work cessation and job changes), as well as absenteeism and presenteeism from paid and unpaid work, and monetise these losses in an equitable manner. Doing so would provide more complete estimates of the productivity burden, ones with greater comparability. The cost estimates discussed in this review (from seven studies [22, 36, 44, 50, 58, 59•, 62] ) varied widely, even after standardisation to 2017 US dollars. Though some of this variation can be attributed to differences in patient populations, and transnational differences in purchasing power, and labour or disability policies, there was considerable heterogeneity in which aspects of productivity loss were included, and how they were valued. For example, paid work losses were valued using overall average wages/earnings in at least one study [44] , and sex-specific (and sometimes age-or education-specific) wages in three [36, 50, 62] . Unpaid work losses were excluded from some studies altogether, whilst one did report time losses from paid and unpaid work, but only determined the costs of paid work loss [62] . Others determined the costs of paid and unpaid work losses, but applied the replacement wage to unpaid work losses [22, 50] , which are typically lower than the overallaverage or sector-specific wages used to value paid work.
These practices limit comparability of estimates, and, more importantly, undervalue the economic contributions of those whose health has left them unable to participate in the paid workforce, as well as those not employed for other reasons (i.e. homemakers, students, and retirees). Eliciting patients' unpaid work losses can also reveal the trade-offs some patients make between time spent on paid and unpaid work [32] , and the resultant costs. Employment offers many benefits, and those with health impairments may continue in their paid work for personal and social rewards, to meet current financial needs, or remain eligible for pensions and insurance. But participation in paid work can leave them with limited time or physical capacity to complete household tasks, especially if their paid working tasks take longer to complete [32] .
Data Sources
The cohorts in most studies in this review were recruited from academic/tertiary medical centres. It may be easier to contact these individuals and collect data from them on short-term work absences, presenteeism, and unpaid work losses; information on potential drivers of productivity loss like disease activity, lung function, pain, and fatigue are also more readily available. But one must consider that patients attending these clinics may not be representative of others with SARDs; they may have more severe disease, or possibly be in a better socioeconomic position. An ideal source of data would build upon those used in the Swedish studies (which linked routinely collected data for the general population with patients' clinical and sociodemographic data), whilst also providing selfreported health status and productivity data for patients, and a sample of the general population. Such linked, populationbased data from SARD and non-SARD individuals would eliminate the need for patients to attribute productivity losses to their SARD specifically, and provide policymakers with better estimates of the incremental productivity burden of these disorders.
Future Directions
An important finding from our review was that the main drivers of lost productivity are often not disease activity or other disease-specific items [20••, 48, 56, 57, 63, 64] , but more generalised factors such as being overweight [63] , pain [21, 40, 48] , depression [40, 63] , cognitive dysfunction [40] , and fatigue [21, 47-49, 56, 63] . Most were cross-sectional studies of prevalent cohorts, so it is unclear whether factors like fatigue and depression contributed to WD, or developed afterwards (and perhaps even resulted from it). More investigations of incident cohorts would help address this. Still, higher baseline fatigue was predictive of WD in one of the longitudinal studies we located [49] , and depression and cognitive function have been predictive of subsequent work loss in SLE [68] .
Another unanswered question is how the productivity burden of these SARDs may have grown, lessened, or shifted over time, as has happened to a limited extent in rheumatoid arthritis (RA) [69, 70] . For example, whilst there was no net change in productivity costs between cohorts of patients with early RA diagnosed in different time periods (1996-1998 and 2006-2009) [70] , the later cohort had fewer costs from sick leave than the early cohort, and more costs from disability pension. Many studies included in this review reported an inverse relationship between educational attainment and WD/productivity loss. With females attaining higher levels of education over the decades, it is possible that the productivity costs of SARDs have decreased alongside. Whilst secular changes could not be evaluated from the current literature, this is a key area for ongoing research, with implications for patients and policymakers. In addition to controlling for changes in patient characteristics and treatment practices over time, such studies should collect data on all aspects of productivity loss, in order to capture secular shifts in costs (i.e. from absenteeism to presenteeism, or paid to unpaid time losses) that may otherwise go unrecognised.
Until now, research on individual SARDs has been limited by the relatively small number of people living with each disorder. However, SARDs have shared pathophysiology and manifestations, and now appear to share some drivers of productivity loss. Several educational, psychological, and exercise interventions have been effective at reducing depression and fatigue in SLE [71, 72] and SjS [73] . Thus, whilst more work is needed, it is possible that productivity losses in SARDs could be mitigated (and perhaps prevented) by lowering levels of pain, fatigue, and depressive symptoms. It is also promising to think that knowledge generated about reducing productivity losses in one SARD could be applied to another.
Conclusions
Whilst the body of literature on productivity losses in SARDs has grown, there is a need (especially in poly/dermatomyositis and systemic vasculitides) for more comprehensive estimates, from incident cohorts, that include absenteeism and presenteeism from paid and unpaid work, calculate costs, and ideally, assess transitions to WD and drivers of these losses on a longitudinal basis. This knowledge would inform decision-making and priority setting, and potentially contribute to the development of strategies and interventions aimed at reducing the economic and societal burden of these lifelong diseases.
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